Aspire Biopharma Holdings Inc. held a special meeting of stockholders on November 4, 2025. At the meeting, stockholders approved granting the board discretionary authority to amend the certificate of incorporation to implement a reverse stock split at a ratio ranging from one-for-five to one-for-forty, to be determined at the board's discretion and effected within one year. Stockholders also approved the issuance of more than 19.99% of the outstanding shares of common stock upon exercise of certain convertible promissory notes, as well as the floor price at which the notes may be converted.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-020891), on November 05, 2025, and is solely responsible for the information contained therein.